137 related articles for article (PubMed ID: 36087065)
1. Clinical evaluation of the OC-Sensor Pledia calprotectin assay.
Butenas J; Ayling RM
Clin Chem Lab Med; 2022 Oct; 60(11):1780-1785. PubMed ID: 36087065
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a faecal calprotectin method using the OC-SENSOR PLEDIA.
O'Driscoll S; Piggott C; Benton SC
Clin Chem Lab Med; 2022 May; 60(6):901-906. PubMed ID: 35285587
[TBL] [Abstract][Full Text] [Related]
3. Faecal calprotectin is not necessarily required as a screen for significant bowel disease in primary care.
Waite MMA; Langmead L; Ayling RM
Ann Clin Biochem; 2022 May; 59(3):171-177. PubMed ID: 34958262
[TBL] [Abstract][Full Text] [Related]
4. Use of faecal immunochemical testing as an alternative to faecal calprotectin in children.
Sandhu K; Naik S; Ayling RM
Ann Clin Biochem; 2021 May; 58(3):230-235. PubMed ID: 33412889
[TBL] [Abstract][Full Text] [Related]
5. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms.
Mowat C; Digby J; Strachan JA; Wilson R; Carey FA; Fraser CG; Steele RJ
Gut; 2016 Sep; 65(9):1463-9. PubMed ID: 26294695
[TBL] [Abstract][Full Text] [Related]
6. Choice of faecal immunochemical test matters: comparison of OC-Sensor and HM-JACKarc, in the assessment of patients at high risk of colorectal cancer.
Chapman CJ; Banerjea A; Humes DJ; Allen J; Oliver S; Ford A; Hardy K; Djedovic N; Logan RF; Morling JR
Clin Chem Lab Med; 2021 Mar; 59(4):721-728. PubMed ID: 33112776
[TBL] [Abstract][Full Text] [Related]
7. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.
Kristensen V; Malmstrøm GH; Skar V; Røseth A; Moum B
Scand J Gastroenterol; 2016; 51(5):548-55. PubMed ID: 26634305
[TBL] [Abstract][Full Text] [Related]
8. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
[TBL] [Abstract][Full Text] [Related]
10. Fecal calprotectin levels in children is more tightly associated with histological than with macroscopic endoscopy findings.
Hradsky O; Ohem J; Mitrova K; Durilova M; Kotalova R; Nevoral J; Kolho KL; Bronsky J
Clin Lab; 2014; 60(12):1993-2000. PubMed ID: 25651733
[TBL] [Abstract][Full Text] [Related]
11. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
12. Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
Högberg C; Karling P; Rutegård J; Lilja M
Scand J Gastroenterol; 2017 Jan; 52(1):69-75. PubMed ID: 27623716
[TBL] [Abstract][Full Text] [Related]
13. Faecal calprotectin: a marker of inflammation throughout the intestinal tract.
Summerton CB; Longlands MG; Wiener K; Shreeve DR
Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):841-5. PubMed ID: 12172403
[TBL] [Abstract][Full Text] [Related]
14. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
[TBL] [Abstract][Full Text] [Related]
15. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
16. Predicting inflammatory bowel disease in children with abdominal pain and diarrhoea: calgranulin-C versus calprotectin stool tests.
Heida A; Van de Vijver E; van Ravenzwaaij D; Van Biervliet S; Hummel TZ; Yuksel Z; Gonera-de Jong G; Schulenberg R; Muller Kobold A; van Rheenen PF;
Arch Dis Child; 2018 Jun; 103(6):565-571. PubMed ID: 29514815
[TBL] [Abstract][Full Text] [Related]
17. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
Mooiweer E; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
Inflamm Bowel Dis; 2014 Feb; 20(2):307-14. PubMed ID: 24374878
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of one or two faecal haemoglobin and calprotectin measurements in patients with suspected colorectal cancer.
Turvill J; Mellen S; Jeffery L; Bevan S; Keding A; Turnock D
Scand J Gastroenterol; 2018 Dec; 53(12):1526-1534. PubMed ID: 30621475
[TBL] [Abstract][Full Text] [Related]
19. Faecal calprotectin: a marker of inflammation throughout the intestinal tract.
Aadland E; Fagerhol MK
Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):823-5. PubMed ID: 12172400
[TBL] [Abstract][Full Text] [Related]
20. Use of a faecal immunochemical test for haemoglobin can aid in the investigation of patients with lower abdominal symptoms.
Godber IM; Todd LM; Fraser CG; MacDonald LR; Younes HB
Clin Chem Lab Med; 2016 Apr; 54(4):595-602. PubMed ID: 26457785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
